CMPX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases...

Stats
Šios dienos apimtis	65 665.00
Vidutinė apimtis	375 306
Rinkos kapitalizacija	184.85M
EPS	$0 ( 2024-03-20 )
Kita pelno data	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.39
ATR14	$0.0120 (0.83%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-08	Boylan James P	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Gray Mary Ann	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Lindahl Richard S	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Gordon Carl L	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Chiniara Ellen	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
93.94
Last 94 transactions
Buy: 28 287 388 \| Sell: 226 920

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: 0.05 (neutral)

Signal:(49.093) Neutral

Compass Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
PIXY	0.935
WTBA	0.915
UPC	0.91
LLNW	0.909
GSMG	0.908
ALXO	0.905
ENNV	0.902
YJ	0.902
BMRA	0.897
LVTX	0.893

10 Labiausiai neigiamai susiję koreliacijos
HHGC	-0.937
KYCH	-0.936
UONE	-0.936
OLED	-0.931
PPD	-0.93
SIBN	-0.927
CDNS	-0.927
NVTS	-0.923
ALYA	-0.923
MELI	-0.923

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Compass Therapeutics, Koreliacija - Valiuta/Žaliavos

-0.20
( neutral )

0.21
( neutral )

0.00
( neutral )

0.09
( neutral )

-0.20
( neutral )

0.22
( neutral )

Compass Therapeutics, Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$-1.90M (0.00 %)
EPS:	$-0.350

FY	2022
Pajamos:	$0
Bruto pelnas:	$-1.90M (0.00 %)
EPS:	$-0.350

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.583

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.566

Financial Reports:

No articles found.

Compass Therapeutics,

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Realaus laiko atnaujinimai Compass Therapeutics, [CMPX]

Upcoming Earnings Alert